Historical Stock Chart
2 Years : From May 2011 to May 2013
Exelixis, Inc. (NASDAQ: EXEL) announced today that Frank Karbe, the
company’s executive vice president and chief financial officer, will
present at the upcoming Deutsche Bank Securities 37th Annual
Health Care Conference at 4:50 p.m. EDT / 1:50 p.m. PDT on Tuesday, May
8, 2012, in Boston. During the presentation, Mr. Karbe will discuss the
company’s development program and plans for cabozantinib, and review the
most recent publicly available data for the compound. He will also
provide a general business update.
The presentation will be webcast and may be accessed via the Event
Calendar page under Investors at www.exelixis.com.
Exelixis, Inc. is a biotechnology company committed to developing small
molecule therapies for the treatment of cancer. Exelixis is focusing its
proprietary resources and development efforts exclusively on
cabozantinib (XL184), its most advanced product candidate, in order to
maximize the therapeutic and commercial potential of this compound.
Exelixis believes cabozantinib has the potential to be a high-quality,
broadly-active, differentiated pharmaceutical product that can make a
meaningful difference in the lives of patients. Exelixis has also
established a portfolio of other novel compounds that it believes have
the potential to address serious unmet medical needs, many of which are
being advanced by partners as part of collaborations. For more
information, please visit the company's web site at http://www.exelixis.com.